Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Praxis Precision Medicines Inc
(NQ:
PRAX
)
72.05
+2.01 (+2.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Praxis Precision Medicines Inc
< Previous
1
2
Next >
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
September 26, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
September 05, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
September 04, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
September 03, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
September 02, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
August 05, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
May 17, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 13, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
May 10, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
April 12, 2024
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming April Conferences
April 05, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
March 28, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
March 27, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
March 26, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Host PRAX-628 Program Update
March 25, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 05, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
March 01, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
January 11, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
January 10, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
January 08, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
January 05, 2024
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings
November 28, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
November 16, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Praxis Precision Medicines, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.